Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
F 5.88 -3.61% -0.22
IOVA closed down 3.61 percent on Thursday, February 6, 2025, on 77 percent of normal volume.
Earnings due: Feb 26
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 1.20%
Wide Bands Range Expansion 1.20%
New 52 Week Closing Low Bearish 4.26%
New 52 Week Low Weakness 4.26%
Wide Bands Range Expansion 4.26%
Gapped Down Weakness 4.26%

   Recent Intraday Alerts

Alert Time
Down 3% about 9 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
Rose Above 20 DMA about 13 hours ago
20 DMA Support about 13 hours ago
10 DMA Support about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Iovance Biotherapeutics, Inc. Description

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Oncology Cancer Treatment Cancer Immunotherapy Cell Therapy Antineoplastic Drugs Melanoma Cancer Cell Lymphocytes Adoptive Cell Transfer Checkpoint Inhibitor Head And Neck Cancer Immunotherapy Products National Cancer Institute Cancer Immunotherapy Product Metastatic Melanoma Pembrolizumab Tumor Infiltrating Lymphocytes Breast And Lung Cancer Ocular Melanoma

Is IOVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 18.33
52 Week Low 5.52
Average Volume 7,029,608
200-Day Moving Average 9.17
50-Day Moving Average 7.30
20-Day Moving Average 6.06
10-Day Moving Average 6.03
Average True Range 0.39
RSI (14) 38.65
ADX 31.28
+DI 17.65
-DI 28.92
Chandelier Exit (Long, 3 ATRs) 6.61
Chandelier Exit (Short, 3 ATRs) 6.69
Upper Bollinger Bands 6.70
Lower Bollinger Band 5.41
Percent B (%b) 0.36
BandWidth 21.26
MACD Line -0.40
MACD Signal Line -0.46
MACD Histogram 0.0652
Fundamentals Value
Market Cap 1.79 Billion
Num Shares 305 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -3.87
Price-to-Sales 19.83
Price-to-Book 2.33
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.34
Resistance 3 (R3) 6.38 6.27 6.26
Resistance 2 (R2) 6.27 6.15 6.25 6.24
Resistance 1 (R1) 6.07 6.08 6.02 6.03 6.21
Pivot Point 5.96 5.96 5.93 5.94 5.96
Support 1 (S1) 5.77 5.85 5.71 5.73 5.55
Support 2 (S2) 5.66 5.77 5.64 5.52
Support 3 (S3) 5.46 5.66 5.50
Support 4 (S4) 5.42